Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Miller

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Retina (Philadelphia, Pa.)|February 16, 2017
EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG SubstudyDavid G Birch, Matthew S Benz, Daniel M Miller, et al.
Retina (Philadelphia, Pa.)|June 22, 2012
Fundus autofluorescence findings of choroidal osteomaRobert A Sisk, Christopher D Riemann, Michael R Petersen, et al.
Ophthalmic Surgery, Lasers & Imaging : the Official Journal of the International Society for Imaging in the Eye|December 7, 2007
Endophthalmitis caused by staphylococcus epidermidis: in vitro antibiotic susceptibilities and clinical outcomesDaniel M Miller, Anil S Vedula, Harry W Flynn, et al.
Ophthalmology|March 12, 2014
Investigation of choroidal neovascularization risk alleles in ocular histoplasmosisMartin F Wilkes, Daniel M Miller, Matthew D Mitchell, et al.
Ophthalmology|December 3, 2011
Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosisDouglas A Cionni, Shawn A Lewis, Michael R Petersen, et al.
American Journal of Ophthalmology|September 15, 2004
The association of prior cytomegalovirus infection with neovascular age-related macular degenerationDaniel M Miller, Diego G Espinosa-Heidmann, Jessica Legra, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|January 7, 2015
Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degenerationAdeel H Shaikh, Brian W Toussaint, Daniel M Miller, et al.
Retina (Philadelphia, Pa.)|July 25, 2022
INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO OCULAR HISTOPLASMOSIS: Ten-Year Follow-UpNicholas E Dudenhoefer, Carl W Noble, Michael R Petersen, et al.
Plos Pathogens|May 10, 2012
Macrophage activation associated with chronic murine cytomegalovirus infection results in more severe experimental choroidal neovascularizationScott W Cousins, Diego G Espinosa-Heidmann, Daniel M Miller, et al.
Ophthalmology|December 3, 2014
Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2Peter A Campochiaro, Raafay Sophie, Michael Tolentino, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Retina (Philadelphia, Pa.)|February 16, 2017
EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG SubstudyDavid G Birch, Matthew S Benz, Daniel M Miller, et al.
Retina (Philadelphia, Pa.)|June 22, 2012
Fundus autofluorescence findings of choroidal osteomaRobert A Sisk, Christopher D Riemann, Michael R Petersen, et al.
Ophthalmic Surgery, Lasers & Imaging : the Official Journal of the International Society for Imaging in the Eye|December 7, 2007
Endophthalmitis caused by staphylococcus epidermidis: in vitro antibiotic susceptibilities and clinical outcomesDaniel M Miller, Anil S Vedula, Harry W Flynn, et al.
Ophthalmology|March 12, 2014
Investigation of choroidal neovascularization risk alleles in ocular histoplasmosisMartin F Wilkes, Daniel M Miller, Matthew D Mitchell, et al.
Ophthalmology|December 3, 2011
Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosisDouglas A Cionni, Shawn A Lewis, Michael R Petersen, et al.
American Journal of Ophthalmology|September 15, 2004
The association of prior cytomegalovirus infection with neovascular age-related macular degenerationDaniel M Miller, Diego G Espinosa-Heidmann, Jessica Legra, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|January 7, 2015
Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degenerationAdeel H Shaikh, Brian W Toussaint, Daniel M Miller, et al.
Retina (Philadelphia, Pa.)|July 25, 2022
INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO OCULAR HISTOPLASMOSIS: Ten-Year Follow-UpNicholas E Dudenhoefer, Carl W Noble, Michael R Petersen, et al.
Plos Pathogens|May 10, 2012
Macrophage activation associated with chronic murine cytomegalovirus infection results in more severe experimental choroidal neovascularizationScott W Cousins, Diego G Espinosa-Heidmann, Daniel M Miller, et al.
Ophthalmology|December 3, 2014
Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2Peter A Campochiaro, Raafay Sophie, Michael Tolentino, et al.
Pageof 5